This trial is testing a new way to treat bladder cancer by combining an immunotherapy drug with radiation.
2 Primary · 5 Secondary · Reporting Duration: From date of registration to date of death due to any cause, assessed up to 4 weeks after radical cystectomy
33 Total Participants · 1 Treatment Group
Primary Treatment: Sasanlimab · No Placebo Group · Phase 2
Age 18+ · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: